Spektrum der Augenheilkunde

, Volume 21, Issue 3, pp 154–159 | Cite as

Systemisches und intravitreales Bevacizumab (Avastin®) bei neovaskulärer altersbezogener Makuladegeneration

  • S. Michels
  • F. Prager
  • W. Geitzenauer
  • B. Lackner
  • S. Sacu
  • G. Weigert
  • K. Kriechbaum
  • K. Polak
  • M. Georgopoulos
  • U. Schmidt-Erfurth
Originalarbeiten

Zusammenfassung

Die wichtige Rolle des vaskulären endothelialen Wachstumsfaktors (VEGF) bei vielen neovaskulären und exsudativen Erkrankungen des Auges hat sich in den letzten Jahren in zahlreichen experimentellen und klinischen Studien herausgestellt. Das therapeutische Konzept der Anti-VEGF-Therapie zeigte sich in zahlreichen prospektiven, kontrollierten Studien mit unterschiedlichen Anti-VEGF-Präparaten als viel versprechend. Besonders bei der neovaskulären altersbezogenen Makuladegeneration (AMD) scheint es möglich geworden zu sein, nicht nur den Visusverlust zu verlangsamen, sondern in einem nicht unerheblichen Anteil der Patienten eine Visusverbesserung zu erreichen. Bevacizumab (Avastin®) ist ein monoklonaler Antikörper, der alle Isoformen des VEGF bindet. Er wurde primär für die systemische Therapie in der Onkologie entwickelt. Prospektive und retrospektive Fallserien zur systemischen und intravitrealen Anwendung von Bevacizumab bei der neovaskulären AMD aber auch bei anderen neovaskulären und exsudativen Erkrankungen des Auges haben sehr viel versprechende Ergebnisse bei insgesamt gutem Sicherheitsprofil gezeigt. Es ist jedoch nicht davon auszugehen, dass Bevacizumab in nächster Zukunft eine Zulassung für die Anwendung in der Augenheilkunde erhalten wird. Wie bei vielen anderen Präparaten in der Augenheilkunde wird die Behandlung mit Bevacizumab weiterhin nur off label oder in klinischen Studien möglich sein. Um die Rolle von Bevacizumab bei der Behandlung verschiedener Augenerkrankungen abschließend bewerten zu können, bleiben jedoch prospektive Langzeitstudien abzuwarten.

Schlüsselwörter

Bevacizumab Neovaskularisation Makuladegeneration VEGF 

Systemic and intravitreal Bevacizumab (Avastin®) in neovascular age-related macular degeneration

Summary

A number of experimental and clinical studies have show the important role of the vascular endothelial growth factor (VEGF) in most neovascular and exudative ocular diseases. The therapeutic concept of an anti-VEGF therapy has been most promising in a number of prospective controlled clinical trials. In the treatment of neovascular age-related macular degeneration (AMD) intravitreal anti-VEGF therapy has shown not only to stabilize vision in most patients, but also to improve vision in a significant number of patients. Bevacizumab (Avastin®) is a monoclonal antibody designed to bind all isoforms of VEGF. It has been primarily developed for the systemic treatment of colon cancer in oncology. But several prospective and retrospective case series evaluating the use of systemic and intravitreal bevacizumab in neovascular AMD and other neovascular and exudative ocular diseases have shown most promising results. Despite the fact that results of large, prospective, long-term studies are currently unavailable, a number of studies have shown anatomic, functional and safety results up to 6 months similar to other anti-VEGF drugs. An approval of bevacizumab in ophthalmology by regulatory agencies cannot be expected in the near future. Similar to a number of drugs in clinical use, bevacizumab will remain available in ophthalmology only as off label treatment or in clinical trials. To clarify the role of bevacizumab for the treatment of a number of neovascular and exudative eye diseases, prospective long-term studies are necessary.

Key words

Bevacizumab Neovascularization Macular degeneration VEGF 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 [6 Suppl 16]: 15–18PubMedGoogle Scholar
  2. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25 (2): 111–118PubMedCrossRefGoogle Scholar
  3. Ferrara N (1999) Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 237: 1–30PubMedGoogle Scholar
  4. Lange T, Guttmann-Raviv N, Baruch L, Machluf M, Neufeld G (2003) VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. J Biol Chem 278 (19): 17164–17169PubMedCrossRefGoogle Scholar
  5. Plate KH, Warnke PC (1997) Vascular endothelial growth factor. J Neurooncol 35 (3): 365–372PubMedCrossRefGoogle Scholar
  6. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW (1996) Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122 (3): 393–403PubMedGoogle Scholar
  7. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, De Jong PT (1997) Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81 (2): 154–162PubMedCrossRefGoogle Scholar
  8. Okamoto N, Tobe T, Hackett SF et al (1997) Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151 (1): 281–291PubMedGoogle Scholar
  9. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE (2000) Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 157 (1): 135–144PubMedGoogle Scholar
  10. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (14): 1419–1431PubMedCrossRefGoogle Scholar
  11. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (14): 1432–1444PubMedCrossRefGoogle Scholar
  12. Chakravarthy U, Adamis AP, Cunningham ET Jr et al (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113 (9): 1508.e1–1508.e25CrossRefGoogle Scholar
  13. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (27): 2805–2816PubMedCrossRefGoogle Scholar
  14. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (23): 2335–2342PubMedCrossRefGoogle Scholar
  15. Tolentino MJ, Husain D, Theodosiadis P et al (2000) Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch Ophthalmol 118 (1): 78–84PubMedGoogle Scholar
  16. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 (6): 1035–1047PubMedCrossRefGoogle Scholar
  17. Mordenti J, Cuthbertson RA, Ferrara N et al (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27 (5): 536–544PubMedGoogle Scholar
  18. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 (4): 336–339PubMedGoogle Scholar
  19. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (4): 331–335PubMedGoogle Scholar
  20. Barron H (2006) Important drug warning. available at: http://www.fda.gov/medwatch/SAFETY/2005/Avastin_dearhcp.pdf. (Accessed October 2006)
  21. Bakri SJ, Snyder MR, Pulido JS et al (2006) Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 26 (5): 519–522PubMedCrossRefGoogle Scholar
  22. Adamis AP, Shima DT, Tolentino MJ et al (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114 (1): 66–71PubMedGoogle Scholar
  23. Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 (3): 262–269PubMedCrossRefGoogle Scholar
  24. Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 (3): 257–261PubMedCrossRefGoogle Scholar
  25. Luthra S, Narayanan R, Marques Le et al (2006) Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26 (5): 512–518PubMedCrossRefGoogle Scholar
  26. Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (3): 363–372.e5PubMedCrossRefGoogle Scholar
  27. Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (4): 383–390PubMedCrossRefGoogle Scholar
  28. Rich RM, Rosenfeld PJ, Puliafito CA et al (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (5): 495–511PubMedCrossRefGoogle Scholar
  29. Bashshur ZF, Bazarbachi A, Schakal A et al (2006) Intravitreal Bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (1): 1–9PubMedCrossRefGoogle Scholar
  30. Costa RA, Jorge R, Calucci D et al (2006) Intravitreal Bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 47 (10): 4569–4578PubMedCrossRefGoogle Scholar
  31. Avery RL, Pearlman J, Pieramici DJ et al (2006) Intravitreal Bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (10): 1695 e1691–e1615CrossRefGoogle Scholar
  32. Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (11): 1344–1349PubMedCrossRefGoogle Scholar
  33. Sakaguchi H, Ikuno Y, Gomi F et al (2006) Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 91 (2): 161–165PubMedCrossRefGoogle Scholar
  34. Yamamoto I, Rogers AH, Reichel E, Yates P, Duker JS (2006) Intravitreal Bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 91 (2): 157–160PubMedCrossRefGoogle Scholar
  35. Iturralde D, Spaide RF, Meyerle CB et al (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 (3): 279–284PubMedCrossRefGoogle Scholar
  36. Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26 (3): 352–354PubMedCrossRefGoogle Scholar
  37. Kahook MY, Schuman JS, Noecker RJ (2006) Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 37 (2): 144–146PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • S. Michels
    • 1
  • F. Prager
    • 1
  • W. Geitzenauer
    • 1
  • B. Lackner
    • 1
  • S. Sacu
    • 1
  • G. Weigert
    • 1
  • K. Kriechbaum
    • 1
  • K. Polak
    • 1
  • M. Georgopoulos
    • 1
  • U. Schmidt-Erfurth
    • 1
  1. 1.Klinik für Augenheilkunde und OptometrieMedizinische Universität WienAustria

Personalised recommendations